Beta-thalassemias are a group of hereditary blood disorders characterized by anomalies in
the synthesis of the beta chains of hemoglobin resulting in variable phenotypes ranging from …

Beta-thalassemia is caused by the reduced (beta+) or absent (beta 0) synthesis of the beta
globin chains of the hemoglobin tetramer. Three clinical and hematological conditions of …

Thalassaemia is one of the most common genetic diseases worldwide, with at least 60 000
severely affected individuals born every year. Individuals originating from tropical and …

Much of our understanding of human physiology, and of many aspects of pathology, has its
antecedents in laboratory and clinical studies of hemoglobin. Over the last century …

The implementation of genetic data for a better prediction of response to medications and
adverse drug reactions is becoming a reality in some clinical fields. However, to be …

A major goal of hemoglobinopathy research is to develop treatments that correct the
underlying molecular defects responsible for sickle cell disease and β-thalassemia. One …

Sickle cell disease (SCD) is an autosomal recessive blood disorder which occurs due to
point mutation in the β-globin chain of hemoglobin. Since the past decades, various …

Pharmacologic induction of fetal hemoglobin (HbF) expression is an effective treatment
strategy for sickle cell disease (SCD) and β-thalassemia. Pomalidomide is a potent structural …

Introduction Sickle cell anemia (SCA) is a hematological genetic disorder caused by a
mutation in the gene of the β-globin. Pharmacological treatments will continue to be an …

Introduction Several herbal medicines have been reported to ameliorate sickle cell disease
(SCD) complications in many African communities. However, no comprehensive review has …